Tosedostat (toe-SEE-doe-stat) is a selective, oral inhibitor of aminopeptidases, enzymes which are required by tumor cells to extract from proteins amino acids necessary for growth and tumor cell survival. Tosedostat has demonstrated significant anti-tumor responses in blood-related cancers and solid tumors in Phase 1 and 2 clinical trials.
There are several ongoing Phase 2 cooperative group-sponsored trials and investigator-sponsored trials evaluating the clinical activity of tosedostat in combination with standard agents in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Data from these signal-finding trials may help inform the appropriate design for a Phase 3 trial. Please see ClinicalTrials.gov for more information.
Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome This study is ongoing but is not recruiting participants.